FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4360614717> ?p ?o ?g. }

• W4360614717 abstract "<h3>Background and Importance</h3> Tofacitinib is a selective inhibitor of the janus kinase family indicated for the treatment of various rheumatological pathologies such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA) and used, off label, in pathologies such as alopecia areata (AA). The Spanish Medicines and Medical Devices Agency (AEMPS) released in July 2021 a safety alert stating that patients over 65 years of age, smokers or ex-smokers and with cardiovascular risk factors or with a predisposition to the development of neoplasms, should not receive treatment with tofacitinib unless no other available therapeutic alternative can be used, based in the results from the ORAL Surveillance clinical trial. Health policy in Andalucía establishes the need to follow-up on the application of the safety notes issued by the AEMPS regarding prescriptions of drugs. <h3>Aim and Objectives</h3> Evaluate the pharmaceutical intervention on the review of tofacitinib prescriptions to ensure their adaptation to the criteria established by the AEMPS, according to the Andalusian regional regulations. <h3>Material and Methods</h3> Retrospective review of tofacitinib prescription in a tertiary hospital. All patients on treatment with tofacitinib from July 2021 to February 2022 were included. Variables collected were age, sex, risk factors included in the health alert and continuation or discontinuation of treatment. <h3>Results</h3> A total of 71 patients receiving tofacitinib treatment were included (mean age: 41 ± 16; sex: 74.6% women). The treatment was discontinued in 25.4% (18/71) of the patients due to inefficacy, adverse reactions or presenting at least one risk factor. However, 74.6% (53/71) of the patients continued treatment, with 43.4% (23/53) having at least one risk factor. Results were shown to the Pharmacy Commission, where the pharmacist developed a protocol regarding tofacitinib safety issues. <h3>Conclusion and Relevance</h3> This is the first experience in our hospital regarding the global monitoring of safety notes released by the AEMPS, endorsed by autonomic regulation. Despite the presence of risk factors, tofacitinib was not withdrawn nor justified in a high percentage of patients. This finding underlines the relevance of systematic patients follow-up and the need to develop protocols agreed by the pharmacists and involved physicians. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest" @default.
• W4360614717 created "2023-03-24" @default.
• W4360614717 creator A5027572623 @default.
• W4360614717 creator A5056336918 @default.
• W4360614717 creator A5057966980 @default.
• W4360614717 creator A5063375155 @default.
• W4360614717 creator A5070164488 @default.
• W4360614717 creator A5080856928 @default.
• W4360614717 date "2023-03-01" @default.
• W4360614717 modified "2023-10-04" @default.
• W4360614717 title "5PSQ-097 Health alert of tofacitinib and pharmaceutical intervention" @default.
• W4360614717 doi "https://doi.org/10.1136/ejhpharm-2023-eahp.301" @default.
• W4360614717 hasPublicationYear "2023" @default.
• W4360614717 type Work @default.
• W4360614717 citedByCount "0" @default.
• W4360614717 crossrefType "proceedings-article" @default.
• W4360614717 hasAuthorship W4360614717A5027572623 @default.
• W4360614717 hasAuthorship W4360614717A5056336918 @default.
• W4360614717 hasAuthorship W4360614717A5057966980 @default.
• W4360614717 hasAuthorship W4360614717A5063375155 @default.
• W4360614717 hasAuthorship W4360614717A5070164488 @default.
• W4360614717 hasAuthorship W4360614717A5080856928 @default.
• W4360614717 hasBestOaLocation W43606147171 @default.
• W4360614717 hasConcept C126322002 @default.
• W4360614717 hasConcept C187212893 @default.
• W4360614717 hasConcept C197934379 @default.
• W4360614717 hasConcept C2426938 @default.
• W4360614717 hasConcept C2776233030 @default.
• W4360614717 hasConcept C2776260265 @default.
• W4360614717 hasConcept C2777575956 @default.
• W4360614717 hasConcept C2778715236 @default.
• W4360614717 hasConcept C2778886723 @default.
• W4360614717 hasConcept C71924100 @default.
• W4360614717 hasConcept C98274493 @default.
• W4360614717 hasConceptScore W4360614717C126322002 @default.
• W4360614717 hasConceptScore W4360614717C187212893 @default.
• W4360614717 hasConceptScore W4360614717C197934379 @default.
• W4360614717 hasConceptScore W4360614717C2426938 @default.
• W4360614717 hasConceptScore W4360614717C2776233030 @default.
• W4360614717 hasConceptScore W4360614717C2776260265 @default.
• W4360614717 hasConceptScore W4360614717C2777575956 @default.
• W4360614717 hasConceptScore W4360614717C2778715236 @default.
• W4360614717 hasConceptScore W4360614717C2778886723 @default.
• W4360614717 hasConceptScore W4360614717C71924100 @default.
• W4360614717 hasConceptScore W4360614717C98274493 @default.
• W4360614717 hasLocation W43606147171 @default.
• W4360614717 hasOpenAccess W4360614717 @default.
• W4360614717 hasPrimaryLocation W43606147171 @default.
• W4360614717 hasRelatedWork W2606332666 @default.
• W4360614717 hasRelatedWork W2755978387 @default.
• W4360614717 hasRelatedWork W2887641776 @default.
• W4360614717 hasRelatedWork W2916556513 @default.
• W4360614717 hasRelatedWork W2967962363 @default.
• W4360614717 hasRelatedWork W3085086630 @default.
• W4360614717 hasRelatedWork W3137618193 @default.
• W4360614717 hasRelatedWork W4226373090 @default.
• W4360614717 hasRelatedWork W4307232541 @default.
• W4360614717 hasRelatedWork W4367721094 @default.
• W4360614717 isParatext "false" @default.
• W4360614717 isRetracted "false" @default.
• W4360614717 workType "article" @default.